M Luis Rodriguez
Overview
Explore the profile of M Luis Rodriguez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiang Y, Xu J, McGovern B, Ranzenigo A, Huang W, Sang Z, et al.
Cell
. 2024 Oct;
187(24):6966-6980.e23.
PMID: 39447570
Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness...
2.
Rosales R, McGovern B, Rodriguez M, Leiva-Rebollo R, Diaz-Tapia R, Benjamin J, et al.
Antiviral Res
. 2024 Jul;
230:105970.
PMID: 39067667
Variants of SARS-CoV-2 pose significant challenges in public health due to their increased transmissibility and ability to evade natural immunity, vaccine protection, and monoclonal antibody therapeutics. The emergence of the...
3.
Schimunek J, Seidl P, Elez K, Hempel T, Le T, Noe F, et al.
Mol Inform
. 2023 Oct;
43(1):e202300262.
PMID: 37833243
The COVID-19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient...
4.
Bouhaddou M, Reuschl A, Polacco B, Thorne L, Ummadi M, Ye C, et al.
Cell
. 2023 Sep;
186(21):4597-4614.e26.
PMID: 37738970
SARS-CoV-2 variants of concern (VOCs) emerged during the COVID-19 pandemic. Here, we used unbiased systems approaches to study the host-selective forces driving VOC evolution. We discovered that VOCs evolved convergent...
5.
Kottur J, White K, Rodriguez M, Rechkoblit O, Quintana-Feliciano R, Nayar A, et al.
PLoS Pathog
. 2023 Jul;
19(7):e1011546.
PMID: 37523415
The RNA N7-methyltransferase (MTase) activity of SARS-CoV-2's nsp14 protein is essential for viral replication and is a target for the development of new antivirals. Nsp14 uses S-adenosyl methionine (SAM) as...
6.
Singh I, Li F, Fink E, Chau I, Li A, Rodriguez-Hernandez A, et al.
J Med Chem
. 2023 Jun;
66(12):7785-7803.
PMID: 37294077
An under-explored target for SARS-CoV-2 is the -adenosyl methionine (SAM)-dependent methyltransferase Nsp14, which methylates the N7-guanosine of viral RNA at the 5'-end, allowing the virus to evade host immune response....
7.
Wei J, Patil A, Collings C, Alfajaro M, Liang Y, Cai W, et al.
Nat Genet
. 2023 Mar;
55(3):471-483.
PMID: 36894709
Identification of host determinants of coronavirus infection informs mechanisms of viral pathogenesis and can provide new drug targets. Here we demonstrate that mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) chromatin remodeling complexes, specifically...
8.
Simba-Lahuasi A, Cantero-Camacho A, Rosales R, McGovern B, Rodriguez M, Marchan V, et al.
Pharmaceuticals (Basel)
. 2022 Dec;
15(12).
PMID: 36558898
Antiviral agents are needed for the treatment of SARS-CoV-2 infections and to control other coronavirus outbreaks that may occur in the future. Here we report the identification and characterization of...
9.
Varona J, Landete P, Lopez-Martin J, Estrada V, Paredes R, Guisado-Vasco P, et al.
Life Sci Alliance
. 2022 Jan;
5(4).
PMID: 35012962
Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over...
10.
Conde E, Vercher E, Soria-Castellano M, Suarez-Olmos J, Mancheno U, Elizalde E, et al.
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34810235
Background: Target antigen (Ag) loss has emerged as a major cause of relapse after chimeric antigen receptor T (CART)-cell therapy. We reasoned that the combination of CART cells, with the...